Advisor Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Advisor Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-200	Closed	–	–	4853
2016 Q3	$0	Hold	200	–	–	﹤0.01%	4860
2016 Q2	$0	Buy	+200	New	+$213	﹤0.01%	4672

Other funds holding NWBO

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Advisor Group's NWBO Position: Q4 2016 in Review

Advisor Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 200 shares.

Advisor Group first reported a position in NWBO in Q2 2016 and held it in 2 quarters. The position peaked at $0 in Q3 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Advisor Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Advisor Group sold 200 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016.
Advisor Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2016 and held it in 2 quarters.
Advisor Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q3 2016.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Advisor Group's 13F filing for Q4 2016, filed 31 Jan 2017.